787596-43-4

Basic information

• Product Name: Methyl 2-chloro-5-Methylisonicotinate
• Synonyms: Methyl 2-chloro-5-Methylisonicotinate
• CAS NO: 787596-43-4
• Molecular Formula: C8H8ClNO2
• Molecular Weight: 185.60762
• Mol File: 787596-43-4.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Methyl 2-chloro-5-Methylisonicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-chloro-5-Methylisonicotinate(787596-43-4)
• EPA Substance Registry System: Methyl 2-chloro-5-Methylisonicotinate(787596-43-4)

Safety Data

• Hazardous Substances Data: 787596-43-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-chloro-5-methylisonicotinate is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
Methyl 2-chloro-5-methylisonicotinate is used as a building block in the production of agrochemicals, contributing to the creation of compounds that can be utilized in agricultural applications.
It is important to handle Methyl 2-chloro-5-methylisonicotinate with caution and follow proper safety protocols, as it can be hazardous if not handled properly.

Upstream product

• 13061-96-6 dihydroxy-methyl-borane 
• 886365-28-2 methyl 5-bromo-2-chloropyridine-4-carboxylate 
• 153034-94-7 2-Fluoro-4-iodo-5-methylpyridine 
• 1227570-92-4 4-iodo-5-methylpyridin-2(1H)-one 
• 951030-56-1 2-chloro-5-methylisonicotinic acid 
• 80-48-8 methyl p-toluene sulfonate 
• 886365-31-7 5-bromo-2-chloropyridine-4-carboxylic acid 
• 60323-96-8 2-chloro-5-methyl-4-nitropyridine 1-oxide 
• 867279-13-8 4-bromo-2-chloro-5-methyl-pyridine 
• 79055-62-2 2-chloro-5-methyl-pyridin-4-ylamine 
• 75-24-1 trimethylaluminum 
• 67-56-1 methanol 

Relevant articles and documents

Substituted tricyclic compound serving as PRMT5 inhibitor and application of substituted tricyclic compound

The invention belongs to the field of medical chemistry, relates to a substituted tricyclic compound serving as a PRMT5 inhibitor and application of the substituted tricyclic compound, and particularly provides a compound shown as a formula (A) or an isom

INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION

Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

PROCESS FOR PREPARING 1-ARYLSULFONYL-PYRROLIDINE-2-CARBOXAMIDE TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST COMPOUNDS AND CRYSTALLINE FORMS THEREOF

The invention relates generally to methods of preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide Transient Receptor Potential channel antagonist compounds of the following structure (I): (I) The invention further relates to solvate and co-crystal polymorphs of crystalline formula (I), and methods of preparation thereof.

PRMT5 INHIBITORS

The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.

APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.